Literature DB >> 9515757

Palliation of malignant dysphagia from oesophageal cancer. Rotterdam Oesophageal Tumor Study Group.

P D Siersema1, J Dees, M van Blankenstein.   

Abstract

Palliative therapies for advanced oesophageal cancer include surgery, radiation therapy, chemotherapy, endoscopic procedures and combinations of these. Of the non-endoscopic modalities is external beam radiation therapy (EBRT) effective and non-invasive. A disadvantage is that relief of dysphagia only occurs over a period of 4-6 weeks. Brachytherapy is more rapid in locally controlling tumour growth and in relieving dysphagia. One of the more commonly used endoscopic procedures is laser therapy, which provides symptomatic relief with low complication rates. Recurrent dysphagia is a problem necessitating repeated treatment sessions. Self-expanding metal stents offer a high degree of palliation and are associated with fewer complications compared with prosthetic tubes. Longer palliation and perhaps even longer survival might be achieved by the combination of different therapies. Most promising are the combination of EBRT plus brachytherapy or chemoradiation. Now is the time to determine which treatment (combination) is best for individual patients.

Entities:  

Mesh:

Year:  1998        PMID: 9515757     DOI: 10.1080/003655298750027272

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  6 in total

1.  What is the optimal management of dysphagia in metastatic esophageal cancer?

Authors:  W C Hanna; M Sudarshan; D Roberge; M David; K A Waschke; S Mayrand; T Alcindor; L E Ferri
Journal:  Curr Oncol       Date:  2012-04       Impact factor: 3.677

2.  Terminal Ileum Perforation as a Consequence of a Migrated and Fractured Oesophageal Stent.

Authors:  V M Reddy; C D Sutton; A S Miller
Journal:  Case Rep Gastroenterol       Date:  2009-04-15

3.  Self-expanding metallic stent placement with an exaggerated 5-cm proximal tumor covering for palliation of esophageal cancer.

Authors:  Mehdi Tahiri; Pasquale Ferraro; André Duranceau; Melanie Berthiaume; Vicky Thiffault; Moishe Liberman
Journal:  Ann Gastroenterol       Date:  2015 Jul-Sep

4.  Bi-weekly chemotherapy of paclitaxel and cisplatin in patients with metastatic or recurrent esophageal cancer.

Authors:  Sang-Hee Cho; Ik-Joo Chung; Sang-Yun Song; Deok-Hwan Yang; Jeong-Rae Byun; Yeo-Kyeoung Kim; Je-Jung Lee; Kook-Joo Na; Hyeoung-Joon Kim
Journal:  J Korean Med Sci       Date:  2005-08       Impact factor: 2.153

5.  Survival and Symptom Relief after Palliative Radiotherapy for Esophageal Cancer.

Authors:  Julia Welsch; Philipp Günther Kup; Carsten Nieder; Veria Khosrawipour; Helmut Bühler; Irenäus A Adamietz; Khashayar Fakhrian
Journal:  J Cancer       Date:  2016-01-01       Impact factor: 4.207

6.  Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy.

Authors:  M B Polee; W C J Hop; T C Kok; F A L M Eskens; M E L van der Burg; T A W Splinter; P D Siersema; H W Tilanus; G Stoter; A van der Gaast
Journal:  Br J Cancer       Date:  2003-12-01       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.